Anti-epiligrin cicatricial pemphigoid and relative risk for cancer

Conleth A. Egan, Zelmira Lazarova, Thomas N. Darling, Carole Yee, Timothy Coté, Kim B. Yancey

Research output: Contribution to journalArticle

146 Scopus citations

Abstract

It is not known whether patients with anti-epiligrin cicatricial pemphigoid (AECP) have an increased risk of malignancy. We calculated the expected numbers of cancers in a cohort of 35 such patients based on respective incidence rates for all cancers in the National Cancer Institute's Surveillance, Epidemiology, and End Results (NCI SEER) Registry. Ten patients in this cohort had solitary solid cancers; eight patients developed cancer after onset of AECP (seven within 14 months). The relative risk (RR) for cancer in this cohort was 6·8 (95% confidence intervals [CI]: 3·3-12·5). AECP seems to be associated with an increased relative risk for cancer.

Original languageEnglish (US)
Pages (from-to)1850-1851
Number of pages2
JournalLancet
Volume357
Issue number9271
DOIs
StatePublished - Jun 9 2001

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Egan, C. A., Lazarova, Z., Darling, T. N., Yee, C., Coté, T., & Yancey, K. B. (2001). Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet, 357(9271), 1850-1851. https://doi.org/10.1016/S0140-6736(00)04971-0